Peking University Third Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

174

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

20 drugs in development

Approved1

Phase 36

Phase 26

Phase 13

Preclinical11

By Therapeutic Area

top 6

Oncology

517%

Immunology

414%

Infectious Disease

27%

Neurology

27%

Musculoskeletal

13%

Metabolic & Endocrine

13%

R&D Momentum

83/100

Pipeline Velocity

58/100

Trial Completion Rate

97/100

Pipeline Concentration

21/100

Pipeline Freshness

62/100

Strategic Signals

↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 16, 2026

Recruiting

Effect and Evaluation of Long-term Isokinetic Training of Knee Joint Under the Influence of Stiffness

Sep 10, 2026

Recruiting

MulticenterClinical Study of Intelligent and Precise Acupuncture and Lifestyle Interventions for Polycystic Ovary Syndrome Guided by Multimodal With Ocular Diagnosis

Sep 10, 2026

Recruiting

Multi-Agent Collaborative Framework for Adverse Drug Reaction Prediction: Evidence-Based Verification and Human-Machine Decision Comparative Study

Earlier

Sep 1, 2026TrialClinical Study to Evaluate the Safety and Efficacy of BCT301 Cell Injection in Patients With Refractory/Recurrent IgG4-Related Disease

Sep 1, 2026TrialClinical Study on Evaluating the Efficacy and Safety of IM19 CAR-T Cell Therapy in Patients With Refractory Systemic Lupus Erythematosus

Aug 25, 2026TrialThe Application of Large Language Model in Emergency Chest Pain Triage

Aug 25, 2026TrialRandomized Controlled Trial of Fuzheng Yangxin Formula in Enhanced Recovery After Coronary Artery Bypass Grafting

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Dermatology(1 drug)

—

Dermatology(1 drug)

Immunology(4 drugs)

—

Immunology(4 drugs)

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(1 drug)

—

Metabolic & Endocrine(1 drug)

Musculoskeletal(1 drug)

—

Musculoskeletal(1 drug)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(5 drugs)

—

Oncology(5 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Unknown / Other(11 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)